Competitor Analysis: Hypoxia-Inducible Factor (HIF)

Publisher: La Merie Publishing
Pages: 13
Format: PDF
Version: Download file
Product Code: LMCA0112
Release Date: April of 2009

100.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Hypoxia-Inducible Factor (HIF)

Product description

The present Competitive Intelligence Report about Hypoxia-Inducible Factor (HIF) provides a competitor evaluation in the field of investigational small molecules and RNA inhibiting HIF-1alpha or HIF-2 for treatment of cancer or acting as HIF agonists to induce angiogenesis as of April 2009.

Hypoxia-inducible factor 1 (HIF-1) is a key regulator of angiogenic and glucose metabolism processes utilised by tumour cells for survival and growth under hypoxic conditions. While HIF-1α protein is found in a wide variety of human primary tumors, it is only produced at very low levels in normal tissue. Because of the important role that HIF-1α plays in regulating the response of growing tumors to hypoxia, the protein is expected to have substantial value as a target for therapeutic intervention. The protein is a key regulator of a large number of genes important in cancer biology, including genes that regulate angiogenesis, cell metabolism, cell proliferation, cell death (apoptosis) and cell invasion. The first molecules inhibiting HIF-1alpha have entered clinical development and others are to follow shortly including small molecules and RNA interfering agents.

The report includes a compilation of current active projects in research and development of HIF targeting small molecules, RNA or DNA. In addition, the report lists company-specific R&D pipelines of HIF targeting molecules. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Index

  • HIF-1alpha Inhibitors
  • HIF-2 Inhibitors
  • HIF Agonists
  • Corporate HIF R&D Pipelines
  • About La Merie

About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top